A Phase 1 interventional study of Paracetamol 500 mg and Paracetamol 1000 mg in Pain, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-12-10.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.
Among the 137 studies testing acetaminophen in Pain, this one is the 123rd largest by enrollment, is one of 6 that started in 2010, is one of 11 in phase 1, and was the 45th registered.
10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Horizon Health Network · Sites in Canada
Ages 19+
University of Gaziantep · Sites in Turkey
Ages 18–75
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18–45 · Women only · Healthy volunteers
Baskent University · Sites in Turkey
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 25 · Phase 4 67
First in 2003; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 66 across 8,511 interventional studies indexed under Pain.
Median enrollment 95 across the 137 interventional studies. Of the 115 that completed or were terminated, 53 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 137 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
30 studies in Pain by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 30 finished, 15 (50%) have results posted.
Among the 30 studies in Pain by GlaxoSmithKline, this one is the 29th largest by enrollment, is one of 4 that started in 2010, is one of 16 in phase 1, and was the 10th registered.
GlaxoSmithKline’s Pain studies by the year they started, since 2003.
4 of the studies testing acetaminophen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07368738Horizon Health NetworkIntravenous Acetaminophen and Ketorolac for Pain Management During Extracorporeal Shockwave Lithotripsy | 2027-04 |
| NCT06613178McGill University Health Centre/Research Institute of the McGill University Health CentreIntravenous Acetaminophen After Cardiac Surgery - Definitive Study | 2027-07-01 |
| NCT07536425Western Galilee Hospital-NahariyaPreoperative Indomethacin and Paracetamol for Pain Management During Oocyte Retrieval in IVF Patients | 2027-10-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 137 studies testing acetaminophen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 30 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This proof of principle study will evaluate an experimental formulation of paracetamol that is being developed for eventual long lasting use. This study is also used for drug safety evaluation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single 2000 mg oral dose of SR paracetamol formulation (2 x 1000 mg) administered with 150 mL of water.
Drug: Paracetamol 1000 mg
A single 1500 mg oral dose of SR paracetamol formulation (2 x 750 mg) administered with 150 mL of water.
Drug: Paracetamol 750 mg
Two single 1000 mg doses of paracetamol (2 x 500 mg/dose) administered orally 6 hours apart, administered with 150 mL of water.
Drug: Paracetamol 500 mg
Standard Paracetamol formulation
Paracetamol Sustained Release formulation
Paracetamol Sustained Release formulation
Median time to reach therapeutic plasma concentration of paracetamol
Time period in hours over which plasma paracetamol concentration is elevated at or above 4 micrograms (μg)/milliliter (mL).
Time frame: Baseline, 15 min, 30 min, 45 min, 1, 1.5 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 14, 15, 16, and 18 hours post-treatment
Area under the plasma concentration-time curve (AUC)
Area under the plasma concentration-time curve from zero to 6 hours (AUC 0-6 hours), 12 hours (AUC 0-12 hours) to be determined. AUC0-t : the area under the plasma concentration-time curve from zero to time t when paracetamol remains detectable. AUC0-∞: the area under the plasma concentration time curve from zero and extrapolated to infinity time.
Time frame: Baseline, 15 min, 30 min, 45 min, 1, 1.5 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 14, 15, 16, and 18 hours post-treatment
Time to maximum plasma concentration (Tmax)
Tmax for paracetamol to be determined.
Time frame: Baseline, 15 min, 30 min, 45 min, 1, 1.5 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 14, 15, 16, and 18 hours post-treatment
Half-life of elimination (T 1/2)
T 1/2 of paracetamol to be determined.
Time frame: Baseline, 15 min, 30 min, 45 min, 1, 1.5 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 14, 15, 16, and 18 hours post-treatment
Elimination rate (Kel)
Kel of paracetamol to be determined.
Time frame: Baseline, 15 min, 30 min, 45 min, 1, 1.5 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 14, 15, 16, and 18 hours post-treatment
Maximum plasma concentration (Cmax)
Cmax of paracetamol to be determined.
Time frame: Baseline, 15 min, 30 min, 45 min, 1, 1.5 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 14, 15, 16, and 18 hours post-treatment
Number of participants with Adverse Events (AEs) and Serious AEs
Safety evaluation
Time frame: Day 1 through Day 14 (follow-up visit)
The record gives a start of May 2010, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen